LT2991988T - Pirol[2,3-d]pirimidino dariniai kaip cb2 receptorių agonistai - Google Patents
Pirol[2,3-d]pirimidino dariniai kaip cb2 receptorių agonistaiInfo
- Publication number
- LT2991988T LT2991988T LTEP14720136.2T LT14720136T LT2991988T LT 2991988 T LT2991988 T LT 2991988T LT 14720136 T LT14720136 T LT 14720136T LT 2991988 T LT2991988 T LT 2991988T
- Authority
- LT
- Lithuania
- Prior art keywords
- pyrrolo
- receptor agonists
- pyrimidine derivatives
- pyrimidine
- derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13166296 | 2013-05-02 | ||
| PCT/EP2014/058648 WO2014177527A1 (en) | 2013-05-02 | 2014-04-29 | Pyrrolo[2,3-d]pyrimidine derivatives as cb2 receptor agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LT2991988T true LT2991988T (lt) | 2017-08-10 |
Family
ID=48190401
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTEP14720136.2T LT2991988T (lt) | 2013-05-02 | 2014-04-29 | Pirol[2,3-d]pirimidino dariniai kaip cb2 receptorių agonistai |
Country Status (35)
| Country | Link |
|---|---|
| US (1) | US9580435B2 (lt) |
| EP (1) | EP2991988B1 (lt) |
| JP (1) | JP6454689B2 (lt) |
| KR (1) | KR20160002857A (lt) |
| CN (1) | CN105164133B (lt) |
| AR (1) | AR096153A1 (lt) |
| AU (1) | AU2014261546B2 (lt) |
| BR (1) | BR112015027394A8 (lt) |
| CA (1) | CA2907691A1 (lt) |
| CL (1) | CL2015003196A1 (lt) |
| CR (1) | CR20150555A (lt) |
| CY (1) | CY1119114T1 (lt) |
| DK (1) | DK2991988T3 (lt) |
| EA (1) | EA028123B1 (lt) |
| ES (1) | ES2635632T3 (lt) |
| HK (1) | HK1213559A1 (lt) |
| HR (1) | HRP20171099T1 (lt) |
| HU (1) | HUE035333T2 (lt) |
| IL (1) | IL242162B (lt) |
| LT (1) | LT2991988T (lt) |
| MA (1) | MA38555B1 (lt) |
| MX (1) | MX2015014081A (lt) |
| MY (1) | MY182237A (lt) |
| NZ (1) | NZ712030A (lt) |
| PE (1) | PE20160039A1 (lt) |
| PH (1) | PH12015502409A1 (lt) |
| PL (1) | PL2991988T3 (lt) |
| PT (1) | PT2991988T (lt) |
| RS (1) | RS56313B1 (lt) |
| SG (1) | SG11201509029PA (lt) |
| SI (1) | SI2991988T1 (lt) |
| TW (1) | TWI680129B (lt) |
| UA (1) | UA116801C2 (lt) |
| WO (1) | WO2014177527A1 (lt) |
| ZA (1) | ZA201507008B (lt) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220140651A (ko) | 2013-09-06 | 2022-10-18 | 에프. 호프만-라 로슈 아게 | 신규의 트라이아졸로[4,5-d]피리미딘 유도체 |
| EP3215506B1 (en) * | 2014-11-07 | 2019-01-02 | F.Hoffmann-La Roche Ag | Triazolo[4,5-d]pyrimidines as agonists of the cannabinoid receptor 2 |
| CN109415366B (zh) | 2016-06-23 | 2022-02-22 | 豪夫迈·罗氏有限公司 | [1,2,3]三唑并[4,5-d]嘧啶衍生物 |
| KR102530131B1 (ko) | 2016-06-23 | 2023-05-10 | 에프. 호프만-라 로슈 아게 | 2형 칸나비노이드 수용체에 대한 친화성을 갖는 [1,2,3]트라이아졸로[4,5-d]피리미딘 유도체 |
| EP3475283B1 (en) | 2016-06-23 | 2021-08-11 | F. Hoffmann-La Roche AG | Novel[1,2,3]triazolo[4,5-d]pyrimidine derivatives |
| WO2018015088A1 (en) | 2016-06-23 | 2018-01-25 | F. Hoffmann-La Roche Ag | Novel [1,2,31triazolo[4,5-d]pyrimidine derivatives |
| WO2022053651A2 (en) | 2020-09-10 | 2022-03-17 | Precirix N.V. | Antibody fragment against fap |
| WO2023203135A1 (en) | 2022-04-22 | 2023-10-26 | Precirix N.V. | Improved radiolabelled antibody |
| WO2023213801A1 (en) | 2022-05-02 | 2023-11-09 | Precirix N.V. | Pre-targeting |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004502642A (ja) | 2000-02-11 | 2004-01-29 | ブリストル−マイヤーズ スクイブ カンパニー | カンナビノイドレセプターモジュレーター、それらの製造方法、および呼吸系および非呼吸系疾患の処置のためのカンナビノイドレセプターモジュレーターの使用 |
| US7271266B2 (en) | 2002-03-28 | 2007-09-18 | Merck & Co., Inc. | Substituted 2,3-diphenyl pyridines |
| DE10219435A1 (de) | 2002-05-02 | 2003-11-13 | Bayer Cropscience Ag | Substituierte Pyrazolo-pyrimidin-4-one |
| AR042667A1 (es) * | 2002-12-26 | 2005-06-29 | Taisho Pharmaceutical Co Ltd | Derivados de pirrolopirimidina y pirrolopiridina sustituidos con un grupo amino ciclico |
| AR051596A1 (es) | 2004-10-26 | 2007-01-24 | Irm Llc | Compuestos heterociclicos condensados nitrogenados como inhibidores de la actividad del receptor canabinoide 1; composiciones farmaceuticas que los contienen y su empleo en la preparacion de medicamentos para el tratamiento de trastornos alimentarios |
| PT1999132E (pt) * | 2006-03-30 | 2012-10-02 | Irm Llc | Azolopirimidinas como inibidores de atividade do recetor canabinóide 1 |
| ES2395583T3 (es) * | 2007-05-10 | 2013-02-13 | Ge Healthcare Limited | IMIDAZOL (1,2-A)PIRIDINAS y compuestos relacionados con actividad frente a los receptores cannabinoides CB2 |
| WO2009032754A2 (en) * | 2007-08-31 | 2009-03-12 | Kalypsys, Inc. | Heterocyclodiazepine cannabinoid receptor modulators for treatment of disease |
| US20100227845A1 (en) | 2007-10-18 | 2010-09-09 | Zhicai Wu | Substituted 1,2,4-oxadiazoles and analogs thereof as cb2 receptor modulators, useful in the treatment of pain, respiratory and non-respiratory diseases |
| UA104010C2 (en) * | 2008-12-18 | 2013-12-25 | Эли Лилли Энд Компани | Purine compounds |
| WO2010118367A2 (en) | 2009-04-10 | 2010-10-14 | Progenics Pharmaceuticals, Inc. | Antiviral pyrimidines |
| KR20120083452A (ko) * | 2009-10-15 | 2012-07-25 | 화이자 인코포레이티드 | 피롤로［2,3-ｄ］피리미딘 화합물 |
| US9321727B2 (en) | 2011-06-10 | 2016-04-26 | Hoffmann-La Roche Inc. | Pyridine derivatives as agonists of the CB2 receptor |
| UA111640C2 (uk) | 2011-11-08 | 2016-05-25 | Ф. Хоффманн-Ля Рош Аг | ПОХІДНІ [1,2,3]ТРИАЗОЛО[4,5-d]ПІРИМІДИНУ ЯК АГОНІСТИ КАНАБІНОЇДНОГО РЕЦЕПТОРА 2 |
| RU2015101818A (ru) | 2012-07-04 | 2016-08-27 | Ф.Хоффманн-Ля Рош Аг | Новые производные адамантила в качестве агонистов каннабиноидных рецепторов 2 |
| MY179412A (en) | 2012-12-07 | 2020-11-05 | Hoffmann La Roche | Pyridine-2-amides useful as cb2 agonists |
| WO2014086705A1 (en) | 2012-12-07 | 2014-06-12 | F. Hoffmann-La Roche Ag | Novel pyridine derivatives |
| LT2928868T (lt) | 2012-12-07 | 2017-10-25 | F. Hoffmann-La Roche Ag | Piridin-2-amidai, tinkami naudoti kaip cb2 agonistai |
| LT2928882T (lt) | 2012-12-07 | 2017-03-27 | F. Hoffmann-La Roche Ag | Pirazino dariniai kaip cb2 receptoriaus agonistai |
| ES2629751T3 (es) | 2013-03-07 | 2017-08-14 | F. Hoffmann-La Roche Ag | Derivados de pirazol novedosos |
| RS57461B1 (sr) | 2013-05-02 | 2018-09-28 | Hoffmann La Roche | Derivati purina kao agonisti cb2 receptora |
-
2014
- 2014-04-29 UA UAA201510730A patent/UA116801C2/uk unknown
- 2014-04-29 WO PCT/EP2014/058648 patent/WO2014177527A1/en active Application Filing
- 2014-04-29 MX MX2015014081A patent/MX2015014081A/es active IP Right Grant
- 2014-04-29 HU HUE14720136A patent/HUE035333T2/en unknown
- 2014-04-29 ES ES14720136.2T patent/ES2635632T3/es active Active
- 2014-04-29 EP EP14720136.2A patent/EP2991988B1/en active Active
- 2014-04-29 KR KR1020157031006A patent/KR20160002857A/ko not_active Application Discontinuation
- 2014-04-29 PL PL14720136T patent/PL2991988T3/pl unknown
- 2014-04-29 JP JP2016511035A patent/JP6454689B2/ja active Active
- 2014-04-29 RS RS20170752A patent/RS56313B1/sr unknown
- 2014-04-29 CN CN201480024215.5A patent/CN105164133B/zh active Active
- 2014-04-29 DK DK14720136.2T patent/DK2991988T3/en active
- 2014-04-29 MA MA38555A patent/MA38555B1/fr unknown
- 2014-04-29 LT LTEP14720136.2T patent/LT2991988T/lt unknown
- 2014-04-29 PT PT147201362T patent/PT2991988T/pt unknown
- 2014-04-29 CA CA2907691A patent/CA2907691A1/en not_active Abandoned
- 2014-04-29 SI SI201430317T patent/SI2991988T1/sl unknown
- 2014-04-29 SG SG11201509029PA patent/SG11201509029PA/en unknown
- 2014-04-29 BR BR112015027394A patent/BR112015027394A8/pt not_active IP Right Cessation
- 2014-04-29 MY MYPI2015703900A patent/MY182237A/en unknown
- 2014-04-29 NZ NZ712030A patent/NZ712030A/en unknown
- 2014-04-29 PE PE2015002323A patent/PE20160039A1/es active IP Right Grant
- 2014-04-29 AU AU2014261546A patent/AU2014261546B2/en not_active Ceased
- 2014-04-29 EA EA201591939A patent/EA028123B1/ru not_active IP Right Cessation
- 2014-04-30 AR ARP140101784A patent/AR096153A1/es unknown
- 2014-04-30 TW TW103115663A patent/TWI680129B/zh not_active IP Right Cessation
-
2015
- 2015-09-21 ZA ZA2015/07008A patent/ZA201507008B/en unknown
- 2015-10-14 CR CR20150555A patent/CR20150555A/es unknown
- 2015-10-16 PH PH12015502409A patent/PH12015502409A1/en unknown
- 2015-10-19 IL IL242162A patent/IL242162B/en active IP Right Grant
- 2015-10-26 US US14/923,186 patent/US9580435B2/en active Active
- 2015-10-30 CL CL2015003196A patent/CL2015003196A1/es unknown
-
2016
- 2016-02-11 HK HK16101493.2A patent/HK1213559A1/zh unknown
-
2017
- 2017-07-18 HR HRP20171099TT patent/HRP20171099T1/hr unknown
- 2017-07-24 CY CY20171100785T patent/CY1119114T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20190361T1 (hr) | Derivati triazolo[4,5-d]pirimidina kao antagonisti cb2 receptora | |
| ZA201506570B (en) | 2-phenylimidazo[1,2-a]pyrimidines as imaging agents | |
| IL242162B (en) | Pyrrolo [2, 3 –d] pyrimidine derivatives as 2cb receptor agonists | |
| AP2014007899A0 (en) | 2-Amino, 6-phenyl substituted pyrido [2,3-D] pyrimidine derivatives useful as RAF kinase inhibitors | |
| PL2776442T3 (pl) | Pochodne [1,2,3]triazolo[4,5-d]pirymidyny jako agoniści receptora kanabinoidowego 2 | |
| HRP20181141T1 (hr) | Derivati purina kao agonisti cb2 receptora | |
| HK1208030A1 (en) | Novel pyrazine derivatives as cb2 receptor agonists cb2 | |
| IL232304A0 (en) | [1,2,3]-Triazolo[4,5-d]pyrimidine derivatives are agonistic for cannabinoid receptor 2 agonists |